Boehringer Ingelheim News Releases
See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.
News Archive
17.06.2008
Boehringer Ingelheim to acquire Actimis Pharmaceuticals
10.06.2008
New data shows pramipexole (Mirapexin®/Sifrol®) can significantly reduce limb pain in patients with Restless Legs Syndrome (RLS)
For medical media, outside the US only
09.06.2008
Closure of the tipranavir POTENT trial
09.06.2008
Boehringer Ingelheim announces first positive health technology assessments for novel oral anticoagulant Pradaxa® (dabigatran etexilate)
For medical media, outside the US only
30.05.2008
Boehringer Ingelheim gets first approval within EU for Actilyse® 2mg to treat catheter dysfunction caused by thrombotic occlusion
For medical media, outside the US only
14.05.2008
PRoFESS® results announced at XVII European Stroke Conference
For medical media, outside the US only
07.05.2008
Women suffering from Decreased Sexual Desire:
Silence hinders diagnosis of the prevalent condition Hypoactive Sexual Desire Disorder(HSDD) For medical media, outside the US only 28.04.2008 European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus®) For medical media, outside the US only 25.04.2008 Data suggests promising overall survival and progression-free survival with Vargatef™ (BIBF 1120) For medical media, outside the US only 17.04.2008 New data confirm pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance for people with Restless Legs Syndrome (RLS) For medical media, outside the US only
Silence hinders diagnosis of the prevalent condition Hypoactive Sexual Desire Disorder(HSDD) For medical media, outside the US only 28.04.2008 European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus®) For medical media, outside the US only 25.04.2008 Data suggests promising overall survival and progression-free survival with Vargatef™ (BIBF 1120) For medical media, outside the US only 17.04.2008 New data confirm pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance for people with Restless Legs Syndrome (RLS) For medical media, outside the US only


